Rodman & Renshaw Downgrades Valeant Pharmaceuticals (VRX) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. FIS
5. BROS
6. QCOM
7. DDOG
8. EW
9. ZG
10. W

Go back to Rodman & Renshaw Downgrades Valeant Pharmaceuticals (VRX) to Neutral

Valeant Reports Third Quarter 2016 Financial Results

November 8, 2016 6:00 AM EST

- Total Revenues of $2.48 billion

- GAAP Cash Flow from Operations of $570 million

- GAAP EPS of  ($3.49)  and Adjusted EPS (non-GAAP) of $1.55

- Revising 2016 Full Year Guidance

LAVAL, Quebec, Nov. 8, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") today announced third quarter 2016 financial results.

"This past quarter, we made further progress toward establishing the new Valeant," said Joseph C. Papa, Chairman and Chief Executive Officer. "We have, where... More